Multiple myeloma: an overview of management

Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and accounts for 2% of all cancer deaths. In the past few decades, there have been huge improvements in life expectancy which have been driven by novel therapeutic agents, autologous stem cell transplants and intensifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Bird, Sarah Anne, Boyd, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065505/
https://www.ncbi.nlm.nih.gov/pubmed/32215370
http://dx.doi.org/10.1177/1178224219868235
_version_ 1783505072879042560
author Bird, Sarah Anne
Boyd, Kevin
author_facet Bird, Sarah Anne
Boyd, Kevin
author_sort Bird, Sarah Anne
collection PubMed
description Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and accounts for 2% of all cancer deaths. In the past few decades, there have been huge improvements in life expectancy which have been driven by novel therapeutic agents, autologous stem cell transplants and intensified supportive care. This review will discuss the pathogenesis of multiple myeloma, current management approaches and the direction of future treatments. In addition, this review will highlight the high burden of symptoms that patients experience and therefore the great benefits that can be gained from specialist palliative care input.
format Online
Article
Text
id pubmed-7065505
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70655052020-03-25 Multiple myeloma: an overview of management Bird, Sarah Anne Boyd, Kevin Palliat Care Soc Pract Review Multiple myeloma represents 2% of all new cancer diagnoses in the United Kingdom and accounts for 2% of all cancer deaths. In the past few decades, there have been huge improvements in life expectancy which have been driven by novel therapeutic agents, autologous stem cell transplants and intensified supportive care. This review will discuss the pathogenesis of multiple myeloma, current management approaches and the direction of future treatments. In addition, this review will highlight the high burden of symptoms that patients experience and therefore the great benefits that can be gained from specialist palliative care input. SAGE Publications 2019-10-09 /pmc/articles/PMC7065505/ /pubmed/32215370 http://dx.doi.org/10.1177/1178224219868235 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Bird, Sarah Anne
Boyd, Kevin
Multiple myeloma: an overview of management
title Multiple myeloma: an overview of management
title_full Multiple myeloma: an overview of management
title_fullStr Multiple myeloma: an overview of management
title_full_unstemmed Multiple myeloma: an overview of management
title_short Multiple myeloma: an overview of management
title_sort multiple myeloma: an overview of management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065505/
https://www.ncbi.nlm.nih.gov/pubmed/32215370
http://dx.doi.org/10.1177/1178224219868235
work_keys_str_mv AT birdsarahanne multiplemyelomaanoverviewofmanagement
AT boydkevin multiplemyelomaanoverviewofmanagement

Ejemplares similares